Relocate equipment to Intrepid for evidence analysis

The Drug Enforcement Administration intends to award a firm-fixed price sole source purchase order to Agilent Technologies, Inc. for the relocation of two GC-MS instruments from SFL8 to SFL1 in El Paso, Texas, to restore them to full operational status for evidence analysis at Intrepid. This acquisition is justified as sole source because Agilent is the only vendor authorized and trained to de-install, package, transport, reinstall, and qualify the specific equipment in accordance with manufacturer specifications, and it possesses proprietary data essential to the process. The procurement is conducted under NAICS code 334516 and exempt from full and open competition under 41 U.S.C. 3304(a)(1), with technical capability and proprietary ownership serving as mandatory pass/fail criteria for any potential respondent. The move must be completed by July 6, 2026, and all services must adhere strictly to Agilent’s technical guidelines without deviation. Although this posting is not a request for proposal, interested parties may submit capability statements by June 15, 2026, at 9:00 a.m. EST to Ms. Angel Barkley at [email hidden] for the government’s consideration in determining whether competitive procedures should be pursued, though no competition is anticipated. The agency has not disclosed the contract value, payment terms, or specific inspection protocols, and no contract clauses, representations, or special requirements beyond the core technical deliverables have been specified in the documentation.